Literature DB >> 15598563

Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate.

Masatoshi Kiuchi1, Kunitomo Adachi, Ayumi Tomatsu, Masao Chino, Shuzo Takeda, Yoshihito Tanaka, Yasuhiro Maeda, Noriko Sato, Naoko Mitsutomi, Kunio Sugahara, Kenji Chiba.   

Abstract

A practical asymmetric synthesis of both enantiomers of the immunosuppressive FTY720-phosphate (2) was accomplished, and the enantiomers were pharmacologically evaluated. Several lipases showed considerable activity and enantioselectivity for O-acylation of N-acetyl FTY720 (3) or N-benzyloxycarbonyl FTY720 (7) in combination with vinyl acetate or benzyl vinyl carbonate as the acyl donors. The synthesis using the lipase-catalyzed acylation as the key step produced the enantiomerically pure (>99.5% ee) enantiomers of 2 in multigram quantities. (S)-Isomer of 2 had more potent binding affinities to S1P(1,3,4,5) and inhibitory activity on lymphocyte migration toward S1P than (R)-2, suggesting that (S)-isomer of 2 is responsible for the immunosuppressive activity after administration of 1. Severe bradycardia was observed in anesthetized rats when (S)-2 was administered intravenously, while (R)-2 had no clear effect on heart rate up to 0.3 mg/kg.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15598563     DOI: 10.1016/j.bmc.2004.10.008

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists.

Authors:  Frank W Foss; Ashley H Snyder; Michael D Davis; Michael Rouse; Mark D Okusa; Kevin R Lynch; Timothy L Macdonald
Journal:  Bioorg Med Chem       Date:  2006-11-01       Impact factor: 3.641

2.  A practical process for the preparation of [(32)P]S1P and binding assay for S1P receptor ligands.

Authors:  Adam J Rosenberg; Hui Liu; Zhude Tu
Journal:  Appl Radiat Isot       Date:  2015-04-17       Impact factor: 1.513

Review 3.  Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii.

Authors:  Kenji Chiba
Journal:  J Antibiot (Tokyo)       Date:  2020-07-17       Impact factor: 2.649

4.  Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist.

Authors:  Takahide Nishi; Shojiro Miyazaki; Toshiyasu Takemoto; Keisuke Suzuki; Yukiko Iio; Katsuyoshi Nakajima; Takashi Ohnuki; Yumi Kawase; Futoshi Nara; Shinichi Inaba; Takashi Izumi; Hiroshi Yuita; Keiko Oshima; Hiromi Doi; Ryotaku Inoue; Wataru Tomisato; Takashi Kagari; Takaichi Shimozato
Journal:  ACS Med Chem Lett       Date:  2011-03-02       Impact factor: 4.345

5.  Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung.

Authors:  Saad Sammani; Liliana Moreno-Vinasco; Tamara Mirzapoiazova; Patrick A Singleton; Eddie T Chiang; Carrie L Evenoski; Ting Wang; Biji Mathew; Aliya Husain; Jaideep Moitra; Xiaoguang Sun; Luis Nunez; Jeffrey R Jacobson; Steven M Dudek; Viswanathan Natarajan; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2009-09-11       Impact factor: 6.914

6.  FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology.

Authors:  Kunitomo Adachi; Kenji Chiba
Journal:  Perspect Medicin Chem       Date:  2007-09-06

7.  Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis.

Authors:  Kenji Chiba; Kunitomo Adachi
Journal:  Pharmaceuticals (Basel)       Date:  2012-05-18

8.  FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system.

Authors:  Felipe V Pereira; Denise C Arruda; Carlos R Figueiredo; Mariana H Massaoka; Alisson L Matsuo; Valquiria Bueno; Elaine G Rodrigues
Journal:  Clinics (Sao Paulo)       Date:  2013-07       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.